pre-IPO PHARMA

COMPANY OVERVIEW

Advicenne is a late-stage pharmaceutical company focusing on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases.


LOCATION


THERAPEUTIC AREAS

  • Kidney Disease
  • Neurological DIsorders
  • Rare Diseases

  • WEBSITE

    https://www.advicenne.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS


    PRESS RELEASES


    Dec 13, 2022

    Advicenne Obtains Orphan Drug Designation for ADV7103 in the United States for the Treatment of Distal Renal Tubular Acidosis (dRTA)


    Nov 3, 2022

    Advicenne Announces Its Upcoming Participation in Two of the Most Important International Investor Conferences


    Oct 5, 2022

    Advicenne Announces the Extension of the Intellectual Property of Its Drug Sibnayal


    Sep 21, 2022

    Advicenne Reports Its First Half Financial Results as of June 30, 2022


    Sep 14, 2022

    Advicenne Updates on Availability of Sibnayal to Patients and Caregivers in Great Britain


    For More Press Releases


    Google Analytics Alternative